On Wednesday, Shares of Rite Aid Corporation (NYSE:RAD), lost -2.36% to $8.68.
Rite Aid Corporation, has completed its previously announced acquisition of Envision Pharmaceutical Services (“EnvisionRx”) from leading global private investment firm TPG and other shareholders in a transaction valued at approximately $2 billion, including approximately $1.8 billion in cash and approximately 27.9 million Rite Aid shares.
EnvisionRx will operate as a wholly owned partner of Rite Aid led by Frank Sheehy and current administration. EnvisionRx’s headquarters will remain in Twinsburg, Ohio.
The transaction, which was declared in February 2015, is predictable to be accretive to Rite Aid’s earnings per share in Rite Aid’s fiscal year 2017.
Rite Aid Corporation, through its auxiliaries, operates a chain of retail drugstores in the United States. The company sells prescription drugs and a range of other merchandise, counting over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other every day and convenience products.
Shares of MeetMe, Inc. (NASDAQ:MEET), inclined 27.78% to $1.84, during its last trading session.
MeetMe, declared it raised its revenue and adjusted EBITDA guidance for its second quarter ending June 30, 2015 based on progress it has made in successfully transitioning administration of its advertising inventory in-house earlier this month.
MeetMe anticipates to declare full second quarter 2015 results in early August at which point it anticipates to also furnish additional revenue and profitability related metrics and updated annual guidance for 2015.
MeetMe, Inc. owns and operates a social network for meeting new people on the Web and on mobile platforms in the United States. The company operates MeetMe.com that provides users with access to various multilingual menu of resources, which promote social interaction, information sharing, and other topics of interest.
Finally, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), ended its last trade with 3.51% gain, and closed at $4.13.
Catalyst Pharmaceuticals, declared top-line results in an open-label, proof-of-concept trial of CPP-109 (vigabatrin) used to treat patients suffering from Tourette’s Disorder (TD) that were refractory to all other previous treatments. One of four patients demonstrated a very clear, clinically noteworthy reduction in tics, and two others showed about a 25% reduction in tics, but without subjective clinical improvement.
This proof-of-concept trial of CPP-109 (Vigabatrin) for Treatment-Refractory Tourette’s Disorder was conducted by Barbara Coffey M.D., M.S., Co-Principal Investigator and Chief of the Tics and Tourette’s Clinical and Research Program at the Icahn School of Medicine at Mount Sinai in New York, in partnership with Dr. Jonathan D. Brodie at the NYU Langone Medical Center, the Co-Principal Investigator and lead inventor of this use of GABA-AT inhibitors. The trial was designed to obtain preliminary data regarding clinical effect, dosage, and tolerability of vigabatrin in subjects at least 18 years of age with a DSM-IV-TR diagnosis of Tourette’s Disorder, who exhibited unsatisfactory response to all preceding treatments.
Catalyst Pharmaceuticals, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders. The company offers Firdapse, a proprietary form of amifampridine phosphate, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
